Vertex Pharmaceuticals Incorporated (VRTX)
$485.22-4.30%Close
SELLBEAR · day 26
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV13.9%–78.5%
- Market cap
- $123.2B
- Beta
- 0.32
- P/E (TTM)
- 28.02
- IV-%ile
- 10
- IV ATM
- 22.5%
- Short % float
- 1.78%
- Days to cover
- 4.2
- SI change
- -4.5%
- 1W
- -3.40%
- 1M
- -6.60%
- vs SPY 1W
- -3.82%
- vs SPY 1M
- -8.66%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 46
- VALUE
- 12
- GROWTH
- 61
- GARP
- 43
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC14.0%
REV YoY-
ROE23.3%
EPS YoY-
ROA16.1%
GROSS86
OP39
NET35
[VALUATION]
P/E TTM28.02
P/E FWD26.15
SECTOR PE20.34
INDUSTRY PE13.84
P/B6.08
P/FCF-
EV/EBITDA21.62
EV/EBIT-
PEG2.07
FCF YIELD-
RISK
INT COV-
D/E9.77
ALTMAN Z-
CURR RATIO3.19
ND/EBITDA-
BETA0.32
Company news
FAQ
- What is LOPJLB’s current signal on VRTX?
- LOPJLB’s latest quantitative signal on Vertex Pharmaceuticals Incorporated (VRTX) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is VRTX in?
- Vertex Pharmaceuticals Incorporated (VRTX) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Vertex Pharmaceuticals Incorporated (VRTX) do?
- Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductanc…